Parse Biosciences has announced a significant milestone in their funding journey, securing a total of $50 million through a Series C equity raise and a debt facility. This round of financing was led by Soleus Capital and witnessed participation from several new and existing investors such as Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen […]
Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, and other biologics for the treatment of difficult-to-treat cancers. Pyxis Oncology’s Series B round also saw the participation of additional new investors – Perceptive […]
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million in a Series B financing round, which was co-led by BVF Partners, Logos Capital, and Janus Henderson Investors. The US biopharma company will use the proceeds for advancing OP-1250, its lead drug candidate in breast cancer, into […]